Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines - Marketscreener.com
| NVSN Stock | MXN 1,960 44.17 2.20% |
Slightly above 62% of Novartis' investor base is looking to short. The analysis of current outlook of investing in Novartis AG suggests that many traders are alarmed regarding Novartis' prospects. Novartis' investing sentiment can be driven by a variety of factors including economic data, Novartis' earnings reports, geopolitical events, and overall market trends.
Novartis |
Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines Marketscreener.com
Read at news.google.com
 |
Novartis Fundamental Analysis
We analyze Novartis' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Novartis is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Novartis AG Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Novartis stock to make a market-neutral strategy. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics with similar companies.
Peers
Novartis Related Equities
| PFE | Pfizer | 0.76 | ||||
| GSKN | GlaxoSmithKline Plc | 0.00 | ||||
| AZNN | AstraZeneca PLC | 1.21 | ||||
| ABBV | AbbVie | 1.61 |
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.